Alnylam Pharmaceuticals Inc (ALNY)vsFortress Biotech Inc Pref Series A (FBIOP)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
FBIOP
Fortress Biotech Inc Pref Series A
$20.43
-0.24%
HEALTHCARE · Cap: $77.81M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 6676% more annual revenue ($4.29B vs $63.26M). ALNY leads profitability with a 12.6% profit margin vs 10.8%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
FBIOP
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Margin of Safety
+13.2%
Fair Value
$13.03
Current Price
$20.43
$7.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Every $100 of equity generates 79 in profit
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
Trading at 12.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : FBIOP
The strongest argument for FBIOP centers on Return on Equity.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : FBIOP
The primary concerns for FBIOP are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a growth stock while FBIOP is a value play — different risk/reward profiles.
FBIOP carries more volatility with a beta of 1.16 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
FBIOP generates stronger free cash flow (204M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 28/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Fortress Biotech Inc Pref Series A
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?